Trial reportClinical cancer research : an official journal of the American Association for Cancer Research2022
Safety, Activity, and Long-term Outcomes of Pomalidomide in the Treatment of Kaposi Sarcoma among Individuals with or without HIV Infection.
Trial report in Clinical cancer research : an official journal of the American Association for Cancer Research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01495598 (A Phase I/II Study of the Safety, Pharmacokinetics and Efficacy of Pomalidomide), which is not on this map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase I/II Study of the Safety, Pharmacokinetics and Efficacy of Pomalidomide (CC-4047) in the Treatment of Kaposi Sarcoma in Individuals With or Without HIV
Who cites it
36 citing papers in PubMed, 48 citations in OpenAlex.
- Selumetinib in Combination with Anti Retroviral Therapy in HIV-associated Kaposi sarcoma (SCART): an open-label, multicentre, phase I/II trial.BMC cancer · 2025Trial
- Clinical Efficacy of the HIV Protease Inhibitor Indinavir in Combination with Chemotherapy for Advanced Classic Kaposi Sarcoma Treatment: A Single-Arm, Phase II Trial in the Elderly.Cancer research communications · 2024Trial
- Outcomes of Kaposi sarcoma in people living with HIV who maintain long-term viral suppression: A prospective case-series.HIV medicine · 2026Article
- Kaposi sarcoma in the era of immunodeficiency: challenges and opportunities for treatment and prevention.Annals of medicine and surgery (2012) · 2026Article
- Precision Imaging to Evaluate Kaposi Sarcoma (PRIME-KS): protocol for a multicountry novel artificial intelligence-based imaging device.medRxiv : the preprint server for health sciences · 2026Article
- Classic Kaposi Sarcoma: Current Treatment Strategies and Emerging Therapeutic Approaches.Cancers · 2026Review
- Overall survival and associated factors among patients with pulmonary Kaposi's sarcoma in sub-Saharan Africa.PLOS global public health · 2026Article
- Kaposi sarcoma in solid organ transplant recipients: updates in epidemiology, diagnosis, treatment and prevention.Frontiers in immunology · 2026Review
- Characteristics and outcomes of Kaposi sarcoma herpesvirus-associated inflammatory cytokine syndrome.Blood advances · 2025Article
- Novel Cereblon-Binding Immunomodulators Have Increased Potency Against Gammaherpesvirus- Associated Lymphomas In Vitro.Journal of medical virology · 2025Article
- Targeting Ikaros and Aiolos with pomalidomide fails to reactivate or induce apoptosis of the latent HIV reservoir.Journal of virology · 2025Article
- Fifth subtype of Kaposi sarcoma in HIV-negative MSM: a retrospective single-arm cohort study from a tertiary care center in NYC from 2000 to 2022.The oncologist · 2025Article
- Primary Effusion Lymphoma Prognostic Score (PEL-PS): A Validated International Prognostic Score in HIV-Associated Primary Effusion Lymphoma.American journal of hematology · 2025Article
- Modern Approach to Manage Patients With Kaposi Sarcoma.Journal of medical virology · 2025Review
- Phase I study of efineptakin alfa (NT-I7) for the treatment of Kaposi sarcoma.Journal for immunotherapy of cancer · 2025Article
- Cancer Immunotherapy Trials Network 12: Pembrolizumab in HIV-Associated Kaposi Sarcoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025Article
- Propranolol: A Promising Therapeutic Avenue for Classic Kaposi Sarcoma.Dermatology practical & conceptual · 2025Article
- Review
- Classic Kaposi sarcoma: Diagnostics, treatment modalities, and genetic implications - A review of the literature.Acta oncologica (Stockholm, Sweden) · 2024Review
- Is inflammation key in Kaposi sarcoma?Blood · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
Abstract
purposeKaposi sarcoma (KS) is caused by Kaposi sarcoma herpesvirus (KSHV), also known as human herpesvirus 8 (HHV-8). KS, which develops most frequently among people with HIV, is generally treated with chemotherapy, but these drugs have acute and cumulative toxicities. We previously described initial results of a trial of pomalidomide, an oral immunomodulatory derivative of thalidomide, in patients with KS. Here, we present results on the full cohort and survival outcomes. PATIENTS AND
methodsParticipants with KS with or without HIV were treated with pomalidomide 5 mg once daily for 21 days per 28-day cycle with aspirin 81 mg daily for thromboprophylaxis. Participants with HIV received antiretroviral therapy. Response was defined by modified version of the AIDS Clinical Trial Group KS criteria. We evaluated tumor responses (including participants who had a second course), adverse events, progression-free survival (PFS), and long-term outcomes.
resultsTwenty-eight participants were enrolled. Eighteen (64%) were HIV positive and 21 (75%) had advanced (T1) disease. The overall response rate was 71%: 95% confidence interval (CI) 51%-87%. Twelve of 18 HIV-positive (67%; 95% CI, 41-87%) and 8 of 10 HIV-negative participants (80%; 95% CI, 44%-97%) had a response. Two of 4 participants who received a second course of pomalidomide had a partial response. The median PFS was 10.2 months (95% CI: 7.6-15.7 months). Grade 3 neutropenia was noted among 50% of participants. In the follow-up period, 3 participants with HIV had other KSHV-associated diseases.
conclusionsPomalidomide is a safe and active chemotherapy-sparing agent for the treatment of KS among individuals with or without HIV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.